Abstract: A filter housing assembly for fluid filtration which may be attached to, and removed from, a filter base by a push-actuated release. The filter housing assembly has a top portion with an ingress port and egress port extending therefrom, and a protrusion extending from the filter housing longitudinally axial center. The ingress and egress port are formed in an hourglass shape. A filter key having a base with a groove for mating with said projection, at least one finger extending from said base, and an electronic circuit component housing attached thereto for receiving a printed circuit board, is connected to the filter housing top portion by mating said top portion protrusion with the filter key groove. Both of said ingress and egress port have at least one cavity for the passage of fluid therethrough, where each cavity is exposed in a direction facing away from the printed circuit board.

Abstract: A method for configuring a system having a wearable optical unit is disclosed. The method includes powering on the system, and in response to the system being powered on, using one or more processors to control the system to: determine whether to cause the system to run a configuration workflow, and in response to determining to cause the system to run the configuration workflow, (a) control the system in connection with configuring an interpupillary distance (IPD) for a user of the system, (b) determine whether the IPD is configured for the user, and (c) in response to determining that the IPD is configured for the user, control the system in connection with configuring a focus of the optical unit.

Abstract: Innovations in game design features of an electronic gaming device are presented. Groups of players can be defined that may win an award that is also available to non-group based players. If the award is won by a group-based player, the award can be distributed to at least a portion of the group members in addition to the player who won the award. A group profile can define criteria for group membership, awards associated with the group, how awards will be distributed among the group, and how and when groups can be altered. Groups can be associated with awards other than those associated with gaming activity. In addition, a value of a gaming award can be increased based on non-gaming activity.

Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).

Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).

Abstract: A body cooling assembly for cooling parts of a body includes a belt that is extendable around a waist. A housing is mounted on the belt includes a top wall, a bottom wall and a perimeter wall that extends between and is attached to the top and bottom wall. The housing has a first aperture and a second aperture for taking in and expelling air. A cooling unit is mounted in the housing. When actuated the cooling unit draws air into the housing, cools the air and dispends the cold air outwardly. A plurality of tubes is fluidly coupled to the housing and in thermal communication with the cooling unit such that air moves through the cooling unit and exits the housing through the tubes. The tubes are positionable on parts of a body and have a plurality of vent holes wherein each tube releases air.

Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).

Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

Abstract: A body cooling assembly for cooling parts of a body includes a belt that is extendable around a waist. A housing is mounted on the belt includes a top wall, a bottom wall and a perimeter wall that extends between and is attached to the top and bottom wall. The housing has a first aperture and a second aperture for taking in and expelling air. A cooling unit is mounted in the housing. When actuated the cooling unit draws air into the housing, cools the air and dispends the cold air outwardly. A plurality of tubes is fluidly coupled to the housing and in thermal communication with the cooling unit such that air moves through the cooling unit and exits the housing through the tubes. The tubes are positionable on parts of a body and have a plurality of vent holes wherein each tube releases air.

Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.